Channel Therapeutics Corporation (CHRO)
Jul 2, 2025 - CHRO was delisted (reason: merged into PTHS)
13.50
0.00 (0.00%)
Inactive · Last trade price on Jul 1, 2025

Channel Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-7.36-7.96-7.38-2.46-0.6-0.66
Other Amortization
0.180.690.190.14--
Stock-Based Compensation
1.991.81.730.11--
Other Operating Activities
-0.36-0.362.43--0.24-
Change in Accounts Payable
1.791.181.630.41-0.83-2.97
Change in Other Net Operating Assets
-0.68-1.140.420.230.07-
Operating Cash Flow
-4.43-5.79-0.98-1.57-1.59-3.63
Short-Term Debt Issued
-0.540.770.4-0.24
Long-Term Debt Issued
---0.81.1-
Total Debt Issued
0.790.540.771.21.10.24
Short-Term Debt Repaid
--0.21----
Total Debt Repaid
--0.21----
Net Debt Issued (Repaid)
0.790.320.771.21.10.24
Issuance of Common Stock
0.086.050.260.420.493.38
Repurchase of Common Stock
-0.08-0.08----
Other Financing Activities
--0.09----
Financing Cash Flow
0.796.211.021.621.593.63
Net Cash Flow
-3.640.420.040.06--
Levered Free Cash Flow
-3.58-6.96-0.64---
Unlevered Free Cash Flow
-3.58-7.16-0.5---
Change in Net Working Capital
0.824.23-2.05---
Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q